This bill mandates that medical care providers review FDA medication guides with the parent, guardian, or state-designated caregiver before prescribing psychotropic drugs to minors under Medicaid. It introduces a new section, RSA 167:3-n, which defines "psychotropic drugs" and outlines the responsibilities of medical care providers. Specifically, providers must provide a physical copy of the FDA medication guide, explain the risks and potential side effects, and obtain written informed consent from the parent, guardian, or caregiver confirming their understanding of the medication's risks. Failure to comply with these requirements may result in penalties, including suspension of Medicaid reimbursements and reporting to the appropriate governing board.

The bill is set to take effect on April 1, 2026, and is expected to have significant fiscal implications. The Department of Health and Human Services anticipates increased costs ranging from $1 million to $2.5 million annually due to the need for investigations into non-compliance and potential disenrollment of providers who refuse to accept Medicaid patients under the new requirements. The bill does not allocate new funding or positions, and the fiscal impact on federal matching funds remains indeterminable.